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Pulmonary fibrosis is a difficult to treat, often fatal disease whose pathogenesis involves
dysregulated TGF-β 1 signaling. CD4+CD25+FoxP3+ Regulatory T cells (“Tregs”) exert
important effects on host tolerance and arise from naïve CD4+ lymphocytes in response
to TGF-β1. However, the precise contribution of Tregs to experimentally induced murine
lung fibrosis remains unclear. We sought to better understand the role of Tregs in
this context. Using a model of fibrosis caused by lung specific, doxycycline inducible
overexpression of the bioactive form of the human TGF-β1 gene we find that Tregs
accumulate in the lung parenchyma within 5 days of transgene activation and that this
enhancement persists to at least 14 days. Anti-CD25 Antibody mediated depletion of
Tregs causes increased accumulation of soluble collagen and of intrapulmonary CD45+Col
Iα1 fibrocytes. These effects are accompanied by enhanced local concentrations of the
classical inflammatory mediators CD40L, TNF-α, and IL-1α, along with the neuroimmune
molecule fibroblast growth factor 9 (FGF-9, also known as “glial activating factor”).
FGF-9 expression localizes to parenchymal cells and alveolar macrophages in this
model and antibody mediated neutralization of FGF-9 results in attenuated detection
of intrapulmonary collagen and fibrocytes without affecting Treg quantities. These data
indicate that CD4+CD25+FoxP3+ Tregs attenuate TGF-β1 induced lung fibrosis and
fibrocyte accumulation in part via suppression of FGF-9.
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INTRODUCTION
Pulmonary fibrosis is a difficult to treat and life-threatening
disease that is characterized by the dysregulated accumulation
of extracellular matrix components in the parenchyma of the
lung (Murray et al., 2012). This disorder is seen in the setting
of autoimmune connective tissue disorders such as scleroderma
(Homer and Herzog, 2010), non-inflammatory disorders such
as gastrointestinal reflux disease (Lee et al., 2010), occupational
exposures such as asbestos (Redlich et al., 2012), and cryptogenic
forms such as idiopathic pulmonary fibrosis (IPF) (Raghu et al.,
2011). Pulmonary fibrosis affects millions of people worldwide
and the incidence is rising (Raghu et al., 2011). The develop-
ment of pulmonary fibrosis is believed to involve a complex
interplay between structural cell death responses and recruitment
of inflammatory cells including collagen-producing fibrocytes.
These events ultimately result in the activation of profibrotic
growth factors such as TGF-β1 and culminate in myofibroblast
transformation and ECM accumulation (Reilkoff et al., 2011).
This paradigm renders TGF-β1-targeted therapies particularly
attractive for the treatment of fibrotic lung disorders however
given its central role in the regulation of cellular survival, pro-
liferation, ECM maintenance, tumorigenesis, and immune regu-
lation, direct inhibition of TGF-β1 might have undesired effects
on tissue homeostasis (Massague, 2012). Thus, examination of
factors that might be used to specifically regulate the pathogenic
aspects of TGF-β1 signaling may facilitate better treatments for
pulmonary fibrosis.
The contribution of CD4+ lymphocytes in general, and reg-
ulatory T cells in specific, to TGF-β1 -induced tissue remodeling
remains unclear (Luzina et al., 2008). In terms of T cell responses,
studies in lymphocyte deficient mice demonstrate that T cells
are not required for the development of fibrosis and remodeling
in the setting of experimentally induced pulmonary pathology
(Helene et al., 1999). However, an emerging body of litera-
ture using sophisticated murine modeling indicates that discrete
Thelper populations exert competing effects on development of
fibrosis and recent studies in humans demonstrate that abnormal-
ities in local and circulating T cell responses are associated with
poor outcomes in IPF (Herazo-Maya et al., 2013; Reilkoff et al.,
2013), thereby suggesting that the T cell contribution to lung
fibrosis is likely more complex than previously thought. Current
paradigms include a role for Th1 cells in the injury responses
that are believed to initiate fibrosis and Th2 cells in the orches-
tration of subsequent remodeling and ECM (Wynn, 2004; Homer
et al., 2011). Regulatory T cells which both respond to and pro-
duce TGF-β1 are thought to control peripheral host tolerance
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by modulation of immune responses. However, evaluation of
these cells in the context of experimentally induced fibrosis has
been challenging, with Tregs demonstrating fibrosis promoting
(Liu et al., 2010; Lo Re et al., 2011) or fibrosis-limiting effects
(Trujillo et al., 2010; Garibaldi et al., 2013) depending on the
model and methods used. Furthermore, the specific contribu-
tion of Tregs to TGF-β1 induced lung fibrosis in specific, and the
mechanisms through which these cells might orchestrate the tis-
sue fibrotic response, remain important but unelucidated areas of
lung biology.
Fibroblast Growth Factor-9, also called “FGF-9” or “glial acti-
vating factor” is a heparin binding, secreted growth factor that
was originally described in glial cells (Miyamoto et al., 1993).
Since its initial description in 1993 this protein has been detected
in a wide variety of tissues where it exerts regulatory effects
on such essential cellular processes embryonic development (Yin
et al., 2011), cellular proliferation (Fakhry et al., 2005), and
migration (Yu et al., 2012), tissue repair (Behr et al., 2010), and
even tumor formation (Yin et al., 2013) and invasion (Teishima
et al., 2012). FGF-9 is also known for its regulation of sex determi-
nation in the developing embryo (Bowles et al., 2010) and for its
regulation of mesenchymal proliferation and epithelial branch-
ing in the developing mouse lung (Yin et al., 2011). In the normal
adult mouse lung, FGF-9 protein is nearly undetectable (Yin et al.,
2013). FGF-9 has also recently been linked to human lung fibrosis
(Coffey et al., 2013) but its role in this disease has to date not been
experimentally defined. In terms of immune regulation, FGF-9
has been only minimally studied but appears to be secreted by
gamma delta T cells where it functions to regulate hair follicle
regeneration (Gay et al., 2013). However, despite its involvement
in multiple cellular processes that would be expected to regulate
repair and remodeling, to date this protein has been little studied
in the context of TGF-β1 induced immunopathogenetic responses
in general.
To better understand these issues, we used transgenic mouse
modeling and antibody mediated neutralization studies to define
the contribution of Tregs to the development of experimentally
induced lung fibrosis in the setting of lung specific, inducible
transgenic TGF-β1 overexpression. Our results indicated that reg-
ulatory T cells exert suppressive effects on collagen accumulation
and fibrocyte recruitment and that these effects are mediated, at
least in part, via inhibition of FGF-9.
MATERIALS AND METHODS
TRANSGENIC MICE
All mouse experiments were approved by the Yale School of
Medicine Institutional Animal Care and Use Committee. The
CC10-tTS-rtTA-TGF-β1 transgenic mice used in this study have
been described previously. These mice use the Clara cell 10-kDa
protein (CC10) promoter to specifically express bioactive human
TGF-β1 to the lung, and were backcrossed for >10 generations
onto a C57BL/6 background (Lee et al., 2004)
DOXYCYCLINE ADMINISTRATION
CC10-tTS-rtTA-TGF-β1 (from hereon called “TGF-β1 mice”)
transgene positive (Tg+) or their wild-type littermate controls
(transgene negative, Tg−), age 8–10 weeks, were given 0.5mg/ml
doxycycline in their drinking water for up to 14 days (Gan et al.,
2011).
NEUTRALIZING ANTIBODY ADMINISTRATION
TGF-β1 Tg+ or TGF-β1 Tg− mice were injected intraperi-
toneally (i.p.) with neutralizing antibodies raised against CD25
(Li et al., 2008; Liu et al., 2010) or FGF-9 (Li et al., 2008). For
CD25 neutralizing studies, 125μg of anti-CD25 (Biolegend #
101906) or IgG2b isotype control (Biolegend #400622) was
injected on days 4, 7, and 10 of doxycycline administration and
mice were sacrificed on day 14. For FGF-9 blocking experiments,
250μg of anti-FGF-9 (R&D #MAB273) or IgG2A isotype con-
trol (R&D #MAB003) were injected on days—1, 2, 5, 8, and 11 of
doxycycline administration and mice were sacrificed on day 14.
BAL AND SACRIFICE
Euthanasia and bronchoalveolar lavage were performed as
previously described (Gan et al., 2011).
FLOW CYTOMETRIC ANALYSIS FOR FIBROCYTES
Following sacrifice of mice, the right upper (RUL) and right
middle (RML) lobes were combined and digested for flow cytom-
etry and total viable cells were quantified using Trypan blue
staining as previously described (Gan et al., 2011). Flow cyto-
metric analyses for Tregs and fibrocytes were performed accord-
ing to our previously published methods. Antibodies against
CD25, CD4, FOXP3, CD45, and appropriate isotype controls
were obtained from BD Pharmingen. Antibody against Collagen-
Iα was obtained from Rockland. Flow cytometry and cell sorting
was performed using a BD FACSCalibur. Data were analyzed
using Flow Jo v 7.5 software (TreeStar, Inc., Ashland, OR).
For all analyses, isotype control staining was subtracted from
true antibody staining to determine the percentage of posi-
tive cells. Fibrocyte detection was performed by first gating
on CD45+ cells in the lung suspensions and then determin-
ing type Iα collagen (Col-Iα), content in these cells as we and
others have described previously (Russell et al., 2012)The per-
centages of these cell present in each unit lung were multiplied
by total viable cell count of mouse digested lung to determine
the absolute number of CD45+Col-Iα+ cells per RUL and RML
(RUL + RML).
SIRCOL ANALYSIS
Right lower lobe (RLL) soluble collagen was measured using the
Sircol Assay (Biocolor Ltd., UK) as we have previously described
(Gan et al., 2011).
HISTOLOGIC ANALYSIS AND IMMUNOHISTOCHEMISTRY
Whole left lungs were harvested from experimental mice for
histological analysis. Formalin-fixed and paraffin-embedded sec-
tions were stained with hematoxylin and eosin to assess gross
morphology or Masson’s trichrome stains to visualize collagen
deposition (Gan et al., 2011). FGF-9 immunohistochemistry
was performed on unstained paraffin sections using anti-FGF-
9 primary antibody followed by alkaline phosphatase-labeled
secondary. Staining was visualized via application of the red
chromogenic substrate (Dako #K60404).
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MULTIANALYTE ELISA
Cytokine measurements were performed on BAL fluid using
Luminex technology as previously described (Gaschler et al.,
2009). Human TGF-β1 concentration was measured by ELISA
(R&D # DB100B).
STATISTICAL ANALYSIS
Normally distributed data are expressed as mean ± s.e.m. and
assessed for significance by Student’s t-test or ANOVA as appro-
priate with Bonferroni post-test. Data that were not normally dis-
tributed were assessed for significance using the Mann-Whitney
U-test where appropriate.
RESULTS
CD4+CD25+FOXP3+ TREGS ACCUMULATE IN THE TGF-β1-EXPOSED
MURINE LUNG
In order to determine whether Tregs accumulate in the lungs of
mice subject to TGFβ1-induced lung fibrosis, TGF-β1 transgene
positive (Tg+) and transgene negative (Tg−, i.e., wild type) mice
were given doxycycline in their drinking water, sacrificed at early
(48 h), intermediate (5 days), and late timepoints (14 days) and
Tregs were quantified using standard FACS-based assessment of
CD4+CD25+FoxP3+ cells on lung digests (Figure 1A). Using
this approach we found that the percentage of CD4+ cells meet-
ing flow cytometric criteria for Tregs were unchanged at the early
timepoint but that compared to Tg−mice, the lungs of Tg+mice
exposed to 5 days of doxycycline contained a 24.3% increase in the
percentage of CD4+ cells that were Tregs (p = 0.0252, Figure 1B)
that was further increased to 34.1% at 14 days (p = 0.0021,
Figure 1B). There was no difference in TGF-β1 induced Treg per-
centages between day 5 and 14 (Figure 1B). These data indicate
that Tregs accumulate in the TGF-β1 exposed murine lung during
the period of fibrogenesis that is dominated by inflammatory cell
recruitment and fibroblast activation, suggesting that the poten-
tial role of Tregs in fibrosis might relate to one or both of these
processes.
ANTIBODY MEDIATED DEPLETION OF TREGS WORSENS TGF-β1
INDUCED LUNG FIBROSIS
Tregs have been reported to have competing effects in several
models of lung fibrosis caused by inhalational bleomycin, LPS
administration, and chronic silica exposure. The data described
above demonstrate a modest increase in Treg accumulate in
the TGF-β1 exposed mouse lung. In order to determine if this
enhancement of Tregs is biologically relevant in our model, TGF-
β1 Tg− and Tg+ mice were exposed to doxycycline and treated
with a well characterized anti-CD25 antibody that has been pre-
viously used for these types of studies (Liu et al., 2010). Because
an increase in Tregs was first detected at 5 days of transgene
activation we initiated dosing on day 4 and repeated antibody
administration every 72 h until the mice had received 14 days of
doxycycline at which point the mice were sacrificed. Flow cytom-
etry confirmed depletion of most Tregs in this model (Figure 2A).
Analysis of samples obtained from these animals demonstrate
that CD25 neutralization increases total lung inflammatory cell
content based on BAL cell counts (Figure 2B). Histologic evalua-
tion of fibrosis performed using Masson’s Trichrome stains found
enhanced collagen accumulation seen both around the airways
and in the alveoli of Treg depleted TGF-β1 mice in comparison
to isotype control TGF-β1 Tg+ mice (Figure 2C). Lung collagen
content assessed by Sircol assay was increased by 21.2% in the
lungs of Treg-depleted TGF-β1 Tg+mice (p = 0.020, Figure 2D).
Importantly, concentrations of bioactive hTGF-β1 did not differ
between these groups (Figure 2E), indicating that the moderate
increase in fibrosis seen in this setting is not related to an increase
in the transgenic fibrotic stimulus. These data indicate that CD25-
mediated Treg depletion leads to increased lung inflammation
and fibrosis, thereby suggesting that immunoregulatory factors
might be mediating these effects.
ANTIBODY MEDIATED DEPLETION OF TREGS INCREASES
INTRAPULMONARY FIBROCYTES
Regulatory T cells are reported to regulate the appearance of
fibrocytes (Garibaldi et al., 2013) in the setting of fibroprolifer-
ative ARDS. Given the association of fibrocytes and pulmonary
fibrosis (Reilkoff et al., 2011), we thought it possible that the
increased collagen accumulation seen in the setting of Treg deple-
tion might be related to enhanced recruitment of fibrocytes. In
order to test this hypothesis, flow cytometry was performed on
lung digests prepared from TGF-β1 Tg+ and Tg− mice that did
and did not receive CD25 mediated Treg depletion and enumer-
ation of fibrocytes was performed following 14 days of transgene
activation. Here we found that the increase in Tg+ lung fibro-
sis seen in the setting of CD25 depletion is accompanied by a
1.61-fold increase in the percentage of CD45+ cells that are Col
Iα1+ fibrocytes (p = 0.04 Figures 3A–E) and a 1.56-fold increase
in the absolute quantities of these cells (p = 0.0445, Figure 3F).
These data indicate that removal of Tregs creates conditions in
the TGF-β1 exposed murine lung that favor the accumulation of
fibrocytes.
ANTIBODY MEDIATED DEPLETION OF TREGS AUGMENTS SOLUBLE
MEDIATORS OF INFLAMMATION AND FGF-9 EXPRESSION
It is increasingly recognized that a complex inflammatory milieu
exists in the fibrotic lung (Homer et al., 2011). Thus, assessments
of BAL cell counts and perhaps even flow cytometric assessment
of lung inflammation may not provide adequate insight into the
factors associated with TGF-β1 induced fibrosis. In order to assess
the concentrations of the soluble mediators that are influenced by
Treg depletion in this model, we performed Luminex based quan-
tification of BAL proteins in TGF-β1 Tg+ mice that did and did
not receive CD25 blocking antibody. This well validated platform
has been used successfully for unbiased biomarker discovery in
humans (Richards et al., 2012) and for detection of novel ther-
apeutic pathways in mice (Gaschler et al., 2009). Here we were
not surprised to find that removal of Tregs substantially increased
concentrations of the TNF superfamily member and costimula-
tory molecule CD40 ligand (Figure 4A) as well as the proinflam-
matory mediators IL-1α (Figure 4B) and TNF-α (Figure 4C).
There was a trend toward increased IL-12p70 (Figure 4D) while
the concentrations of IL-10 (Figure 4E), IL-4 (Figure 4F) and
the alternatively activated macrophage marker MDC (Figure 4G)
were unchanged when Tregs were depleted. We did note an unex-
pected increase in FGF-9 (Figure 4H), a neuroimmune molecule
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FIGURE 1 | CD4+CD25+FoxP3+ Tregs accumulate in the TGF-β1-
exposed murine lung. (A) Flow cytometric detection of Tregs in the
TGF-β1 Tg+ lung. TGF-β1 Tg+ and Tg− (not shown) mice were
administered doxycycline in their drinking water for 2, 5, or 14 days,
sacrificed, and flow cytometry was performed on lung digests. Live
cells were analyzed and percent of cells triple positive for CD4, CD25,
and FoxP3 was determined as shown. One representative mouse
sample from each group of TGF-β1 Tg+ mice is depicted. (B)
Comparison of Treg percentages in TGF-β1 Tg+ and Tg− lungs at early
and late time points during transgene activation. ∗p < 0.05 compared to
the 48 h time point. ∗∗p < 0.01 compared to the 48 h time point. n > 4
mice/group, performed in triplicate.
with manifold effects on embryonic development that may be
implicated in human lung fibrosis (Coffey et al., 2013). The
full results of these studies are presented in Table 1. These data
indicate that Treg depletion increases concentrations of T cell
activation markers and classical inflammatory mediators without
affecting Th2 cytokines in the TGF-β1 exposed murine lung. In
addition, these effects are accompanied by increased expression of
FGF-9.
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FIGURE 2 | Depletion of Tregs exacerbates TGF-β1 induced lung fibrosis.
TGF-β1 Tg+ and Tg− mice were administered doxycycline for 14 days during
which they were injected i.p. with anti-CD25 antibody on days 4, 7, and 10. All
mice were sacrificed on day 14, BAL was performed, and lungs were
processed for flow cytometry, Sircol assay, and histology as described in the
Methods. (A) Percentage of live lung cells that are CD25+/CD4+/FoxP3+ as
determined by flow cytometry performed on combined right upper and
middle lobes. (B) BAL leukocyte cell concentrations (absolute # per μl). (C)
Trichrome staining of paraffin embedded lung sections from TGF-β1 Tg+ and
Tg− mice treated with anti-CD25 antibody or isotype control. Scale bar = 250
microns. (D) Lung collagen content measured by Sircol assay performed on
the right lower lobe (RLL). (E) Human (transgenic) bioactive TGF-β1
concentrations in mouse BAL fluid as determined by ELISA. ∗p < 0.05. n > 4
mice/group, performed in triplicate.
FGF-9 EXPRESSING CELLS ARE INCREASED IN THE TGF-β1 EXPOSED
MURINE LUNG
FGF-9, or glial activating factor, is a neuronal protein that regu-
lates gonadal differentiation in the developing embryo (Dinapoli
et al., 2006). This molecule is also a potent mitogen with signifi-
cant stimulatory effects on a wide variety of biological processes
including lung development in utero (Colvin et al., 2001) and
tumorigenesis (Yin et al., 2013). While increased detection of
FGF-9 has been reported in lungs of patients with IPF (Coffey
et al., 2013) a role for FGF-9 in the regulation of experimen-
tally induced lung fibrosis has yet to be described. In order to
determine whether the increased FGF-9 seen in the setting of
Treg depletion might be pathogenic, we used immunohistochem-
istry to determine the site of expression of FGF-9 in the setting of
TGF-β1 overexpression (Figures 5A–C). Here we found that, con-
sistent with prior reports, FGF-9 expression was undetectable in
the naïve Tg—adult mouse lung (Figure 5C). In contrast, in the
setting of transgenic TGF-β1 overexpression, immunodetection
of FGF-9 was markedly increased in cells bearing the morphol-
ogy of alveolar macrophages and epithelial cells (Figures 5A,B).
Moreover, we detected a 1.75-fold fold increase in the quan-
tity of FGF-9+ cells in the lungs of TGF-β1 Tg+ mice treated
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FIGURE 3 | Depletion of Tregs increases intrapulmonary fibrocytes in the
TGF-β1 exposed murine lung. Fibrocyte detection by flow cytometry of
digested lungs from TGF-β1 Tg+ mice given doxycycline for 14 days and
treated with isotype and anti-CD25 antibody. Panel (A) demonstrates the
CD45+ population that was selected for analysis and Panel (B) presents
FITC-detected intracellular isotype control (X axis) vs. CD45-PerCP (Y axis)
that was used to determine the negative gate. (C,D) CD45+ ColIα1+ dot
plots in lung digests obtained from doxycycline treated TGF-β1 Tg+ mice
treated with (C) isotype control or (D) CD25 neutralizing antibody. Percentage
(E) and concentration (F) of CD45+ ColIα1+ cells in lung digests of TGF-β1
Tg+ and Tg− mice treated with anti-CD25 antibody or isotype control.
∗p < 0.05, ∗∗p < 0.01. n > 4 mice/group, performed in triplicate.
with anti-CD25 antibody relative to those administered isotype
control (p = 0.007, Figure 5C), indicating that Treg depletion
increases the presence of FGF-9+ cells in this experimental
system.
ANTIBODY MEDIATED NEUTRALIZATION OF FGF-9 AMELIORATES
TGF-β1 INDUCED PULMONARY FIBROSIS
We next sought to assess whether FGF-9 promotes TGF-β1
induced lung fibrosis in our model. Because FGF-9 null mice
are embryonic lethal (Colvin et al., 2001) we employed antibody
mediated neutralization of FGF-9 using a well validated blocking
antibody approach (Li et al., 2008). Here, TGF-β1 Tg− and Tg+
mice were randomized to receive intraperitoneal injections of
FGF-9 neutralizing antibody or isotype control every 72 h from
the night prior to doxycycline initiation until 14 days at which
point they were sacrificed. Using this approach we found no
reduction in BAL cell counts (Figure 6A) and a 55.3% reduction
in lung collagen content (p = 0.027, Figure 6B). Examination of
lung histology confirmed these findings (Figure 6C). These data
indicate that FGF-9 neutralization reduces collagen accumulation
and fibrosis in the TGF-β1 exposedmurine lung without affecting
inflammation.
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FIGURE 4 | Depletion of Tregs amplifies expression of inflammatory
markers and FGF9 in the TGF-β1 exposed mouse lung. Soluble
mediators in the BAL fluid of TGF-β1 Tg+ mice given doxycycline for 14
days and treated with isotype or anti-CD25 neutralizing antibody were
quantified by Luminex technology as described. (A) CD40L. (B) IL-1alpha.
(C) TNF-alpha. (D) IL-12p70. (E) IL-10. (F) IL-4. (G) MDC. (H) FGF-9. Full
results are presented in Table 1. P-values are indicated for each marker.
n > 4 mice/group.
ANTIBODY MEDIATED NEUTRALIZATION OF FGF-9 REDUCES
DETECTION OF FIBROCYTES IN THE TGF-β1 EXPOSED MURINE LUNG
Last, in order to determine whether FGF-9’s effects on fibro-
sis extend to an immunomodulatory role as well, we quantified
fibrocytes in the lungs of TGF-β1 Tg− and Tg+ mice that were
subject to FGF-9 neutralization. Here, compared to sham-treated
mice, we found a 57.5% reduction in percentages of CD45+ cells
that co-express Col Iα1+ (p = 0.009, Figure 6D) and more than
twelve-fold reduction in total quantities of these cells (Figure 6E,
p = 0.008) in the lungs of TGF-β1 Tg+ mice that were treated
with FGF-9 blockade. Importantly, percentages of Tregs were not
influenced by this intervention (Figure 6F), indicating that FGF-
9’s effects on fibrosis and fibrocytes are enacted downstream of
Tregs.
www.frontiersin.org May 2014 | Volume 5 | Article 80 | 7
Peng et al. Tregs and FGF-9
Table 1 | P-Values of BAL multiplex comparing isotype vs. anti-CD25
treated Tg+mice.
Analyte P-value
Apolipoprotein A1 0.547
CD40 0.327
CRP 0.807
Endothelin-1 0.681
Eotaxin 0.932
Epidermal growth factor 0.989
Factor VII 0.98
Fibrinogen 0.199
Basic FGF 0.566
GST-alpha 0.075
GM-CSF 0.994
KC/GRO 0.091
Haptoglobin 0.037
IgA 0.432
Interferon gamma 0.324
IP-10 0.416
IL-1β 0.782
IL-11 0.15
IL-12p70 0.268
IL-17A 0.341
IL-18 0.964
IL-2 0.258
IL-3 Undetectable
IL-5 0.384
IL-6 0.417
IL-7 0.423
LIF 0.697
Lymphotactin 0.7633
M-CSF-1 0.295
MIP-1α 0.912
MIP-Iβ 0.465
MIP-1g 0.164
MIP-2 0.546
MIP-3β 0.936
MDC 0.729
MMP-9 0.905
MCP-1 0.619
MCP-3 0.096
MCP-5 0.174
MPO 0.329
Myoglobin 0.064
OSM 0.238
SAP 0.968
SGOT Undetectable
SCF 0.4066
RANTES 0.350
TPO 0.387
TF 0.139
TIMP-1 mouse 0.123
VCAM-1 0.964
VEGF-A 0.785
vWF 0.258
Analytes with significant changes are reported in the text.
FIGURE 5 | Treg depletion results in increased accumulation of FGF-9
expressing cells in the fibrotic mouse lung. (A,B) Immunohistochemisty
for FGF-9 (red) on TGF-β1 Tg+ mice given doxycycline for 14 days and
treated with isotype control or anti-CD25 antibody. Tissue sections were
counterstained with hematoxylin. (C) Composite data represented as
number of FGF-9+ cells per high power field. n > 4 mice/group. ∗∗p < 0.01.
DISCUSSION
These data lend new insight into the mechanism(s) through
which Tregs might regulate experimentally induced pulmonary
fibrosis. Specifically, they demonstrate that in the setting of
inducible overexpression of TGF-β1, enhanced quantities of Tregs
are detected within 5 days of transgene activation and that this
increase is sustained until at least 14 days. Antibody medi-
ated depletion of Tregs leads to accumulation of collagen and
increased detection of intrapulmonary fibrocytes. These find-
ings are accompanied by a local increase in mediators asso-
ciated with T cell activation and Th1 inflammation, as well
as increased concentrations of FGF-9 in the TGF-β1 exposed
murine lung. Antibody mediated FGF-9 neutralization reduces
TGF-β1 induced fibrosis and accumulation of fibrocytes. These
data present evidence that Tregs attenuate TGF-β1 induced
lung fibrosis and fibrocyte accumulation in part via suppres-
sion of FGF-9. While FGF-9 has been shown to be expressed
in fibrotic human lung and human fibroblasts in response to
TGF-β1 (Coffey et al., 2013) the studies presented here pro-
vide a putative mechanistic role for this molecule in pulmonary
fibrosis via the accumulation of fibrocytes within the TGF-β1
exposed lung.
The study of Tregs in experimentally induced lung fibrosis has
yielded conflicting and at times contradictory results. For exam-
ple, studies involving cytokine manipulation or Treg transfers in
bleomycin fibrosis (Trujillo et al., 2010) or LPS induced acute lung
injury (Garibaldi et al., 2013) models demonstrate a protective
role for these cells. In contrast, several studies using the silico-
sis model indicate that Tregs possess profibrotic properties (Liu
et al., 2010; Lo Re et al., 2011). The disparity of these findings
is not surprising when one considers the experimental variance
Frontiers in Pharmacology | Inflammation Pharmacology May 2014 | Volume 5 | Article 80 | 8
Peng et al. Tregs and FGF-9
FIGURE 6 | FGF-9 blockade reduces lung fibrocyte accumulation
and fibrosis in TGF-β1 transgenic mice. TGF-β1 Tg+ and Tg− mice
were administered 14 days of doxycycline and injected i.p. with
either FGF-9 neutralizing antibody or isotype control on days—1, 2,
5, 8, and 11. (A) BAL leukocyte concentration (absolute # per μl).
(B) Lung collagen content as measured by Sircol assay performed
on the right lower lobe (RLL). (C) Trichrome staining of paraffin
embedded lung sections from TGF-β1 Tg+ mice treated with isotype
control (left) or anti-FGF-9 antibody (right). Scale bar = 100 microns
(D,E) Percentages (D) and absolute number (E) of fibrocytes
(CD45+ColIα1+) in lung digests as determined by flow cytometry.
(F) Quantity of Tregs (expressed as percentage of CD4 cells that
are CD25+FoxP3+) in lung digests as determined by flow cytometry.
n = 5 mice/group. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
in models used and methods of study. In our work, we find that
antibody mediated Treg removal worsens fibrosis and that these
effects are accompanied by an increase in classical inflamma-
tory mediators such as TNF-α and IL1-α. The source of these
mediators is not entirely clear but because similar studies per-
formed in LPS-treated Rag null mice demonstrate similar findings
(Aggarwal et al., 2010), it is likely that this effect is at least par-
tially T cell independent and relates to increased production by
macrophages and structural cells such as the airway and alveolar
epithelia. Because we also find an increase in classical inflamma-
tory mediators in the setting of Treg depletion, we believe that
Tregs function at the tissue level to cease damage and restore
homeostasis via modulation of tissue inflammation and/or via
direct engagement of local cytoprotective responses (D’Alessio
et al., 2009). This concept is important because it suggests that
rather than simply amplifying existing cell death responses, an
absence of functional Tregs might permit or perhaps even induce
tissue injury in the setting of profibrotic stimuli. Whether this
conclusion will hold true when studied in other modeling systems
and, more importantly, in the context of human disease, remains
to be seen.
Our study indicates that Treg removal causes enhanced
intrapulmonary accumulation of CD45+ ColIα1+ fibrocytes.
Fibrocytes are a leukocyte derived mesenchymal cell population
that are implicated in the immunologic events leading to the
development of tissue fibrosis (Reilkoff et al., 2011). The data
presented herein suggest that the enhanced local levels of FGF-9
caused by Treg depletion create a situation favoring the differen-
tiation, recruitment, and/or retention of fibrocytes. In our system
the Tregs do not themselves produce FGF-9, but rather modulate
its production by structural cells and/or alveolar macrophages. To
our knowledge, these are the first data to propose a role for either
FGF-9 or alveolar macrophages in the regulation of fibrocyte
accumulation. It is also possible that the increased levels of CD40L
seen in our model stimulate a proinflammatory fibrocyte phe-
notype characterized by secretion of TNF-α as has been recently
described in the setting of Grave’s ophthalmopathy (Gillespie
et al., 2012), though this hypothesis will require more evaluation.
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Further work will be required to dissect the precise relationship
between Tregs, macrophages, fibrocytes, and inflammation in the
context of fibroproliferative lung disease.
FGF-9 has been previously shown to regulate TGF-β1 induced
cell proliferation in the developing palate (Iwata et al., 2012)
and is induced in human lung fibroblasts in response to TGF-
β1 stimulation (Coffey et al., 2013). Given its well documented
stimulatory effects on organ development, cell proliferation, and
angiogenesis it is not surprising that FGF-9 would be involved
in tissue injury and pathologic remodeling. In the developing
lung, FGF-9 engages FGFR2 and FGFR3 to regulate epithelial
branching and mesenchymal proliferation via differentially reg-
ulated Wnt signaling (Yin et al., 2011). The nature of FGF-9
signaling in the setting of experimentally induced fibrosis remains
uneludicated but may involve regulation of cell death responses,
immunomodulation, or regulation of fibroblast proliferation.
FGF-9 has been reported to be expressed in hyperplastic epithe-
lial cells, myofibroblasts, and perivascular smooth muscle cells in
the lungs of patients with IPF. To date, expression on inflamma-
tory cells in the setting of tissue fibrosis has not been reported.
Indeed, our detection of FGF-9+ alveolar macrophages in the
context of an inflammatory milieu is consistent with previous
findings that FGF-9 expression is enhanced in settings charac-
terized by increased expression of IL-1α (Ueng et al., 2005).
However, several questions remain. For example, we have not
determined the receptor(s) or mechanism(s) through which FGF-
9 regulates TGF-β1 induced fibrosis and fibrocyte accumulation
though it is likely that FGFR2 and/or FGFR3 are involved. We
have not defined the macrophage subpopulation(s) that pro-
duce FGF-9 in this model and we also have not ruled out
expression by other cell types, such as gamma delta T cells, at
different time points. Nevertheless, our data indicate that FGF-
9 joins other neuroimmune molecules such as Semaphorin 7a
(Reilkoff et al., 2013) and Plexin C1 (Gan et al., 2011) as impor-
tant regulators of TGF-β1 associated fibrosis and/or fibrocyte
accumulation.
In conclusion, these studies frame Tregs as important sup-
pressors of TGF-β1 induced lung pathology and reveal FGF-9 as
a downstream mediator of Treg activity. Further studies in this
area might facilitate better understanding of tissue repair and
remodeling.
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